FullHope Biomedical Co., Ltd.   Report issue

For profit Phase 1
Founded: Taipei Taiwan (2012)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2014
NCT02882659
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

dendritic cell activated cytokine-induced killer cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 1)

Colorectal Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1